title: The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma.
abstract: Cutaneous melanoma is the most deadly cutaneous neoplasm. In order to guide treatment decisions and follow-up of melanoma patients, guidelines for the management of melanoma in Switzerland were inaugurated in 2001 and revised in 2006 and 2016. Recent data on surgical and medical treatments from randomised trials necessitated modification of the treatment and follow-up recommendations.
authors.affiliation: Skin Cancer Centre, Dept. of Dermatology, University Hospital of Zurich, Switzerland.
authors.forename: Reinhard
authors.initials: R
authors.lastname: Dummer
authors.affiliation: Dept. of Oncology, Kantonalspital St. Gallen, Switzerland.
authors.forename: Marco
authors.initials: M
authors.lastname: Siano
authors.affiliation: Skin Cancer Centre, Dept. of Dermatology, University of Bern, Inselspital, Bern, Switzerland.
authors.forename: Robert E
authors.initials: RE
authors.lastname: Hunger
authors.affiliation: Division of Plastic Surgery and Hand Surgery, University Hospital of Zurich, Switzerland.
authors.forename: Nicole
authors.initials: N
authors.lastname: Lindenblatt
authors.affiliation: Skin Cancer Centre, Dept. of Dermatology, University Hospital of Zurich, Switzerland.
authors.forename: Ralph
authors.initials: R
authors.lastname: Braun
authors.affiliation: Dept. of Oncology, University Hospital of Lausanne, Switzerland.
authors.forename: Oliver
authors.initials: O
authors.lastname: Michielin
authors.affiliation: Dept. of surgical Pathology, University Hospital of Zurich, Switzerland.
authors.forename: Daniela
authors.initials: D
authors.lastname: Mihic-Probst
authors.affiliation: Dept. of Oncology, Kantonalspital Chur, Switzerland.
authors.forename: Roger
authors.initials: R
authors.lastname: von Moos
authors.affiliation: Dept. Radiation Oncology, University Hospital of Zurich, Switzerland.
authors.forename: Yousef
authors.initials: Y
authors.lastname: Najafi
authors.affiliation: Dept. Radiation Oncology, University Hospital of Zurich, Switzerland.
authors.forename: Merlin
authors.initials: M
authors.lastname: Guckenberger
authors.affiliation: Dept. of Dermatology, University Hospital of Basel, Switzerland.
authors.forename: Andreas
authors.initials: A
authors.lastname: Arnold
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D062109:Dermatologic Surgical Procedures; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D007211:Indoles / Q000627:therapeutic use; D000074324:Ipilimumab; D008197:Lymph Node Excision; D008545:Melanoma / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D000077594:Nivolumab; D010091:Oximes / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D018714:Radiotherapy, Adjuvant; D021701:Sentinel Lymph Node Biopsy; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy*; D013449:Sulfonamides / Q000627:therapeutic use; D013557:Switzerland; D000077204:Temozolomide; D000077484:Vemurafenib
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D007093:Imidazoles; D007211:Indoles; D000074324:Ipilimumab; D010091:Oximes; D013449:Sulfonamides; D000077484:Vemurafenib; D000077594:Nivolumab; D003606:Dacarbazine; C561627:dabrafenib; D000077204:Temozolomide